Primary Biliary Cholangitis Market Report 2026

The primary biliary cholangitis market size has grown strongly in recent years. It will grow from $1.06 billion in 2025 to $1.15 billion in 2026 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to improved understanding of autoimmune liver diseases, increased availability of diagnostic testing, expansion of specialty liver clinics, rising clinical awareness of pbc symptoms, development of standard pharmacological treatments.

The primary biliary cholangitis market size is expected to see strong growth in the next few years. It will grow to $1.6 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to increasing investments in rare disease research, rising adoption of personalized medicine approaches, expansion of advanced imaging diagnostics, growing pipeline of targeted therapies, increasing focus on early-stage disease management. Major trends in the forecast period include increasing focus on targeted drug therapies, rising adoption of advanced diagnostic imaging techniques, growing integration of biomarker-based disease monitoring, expansion of personalized treatment approaches, enhanced emphasis on early disease detection.

The increase in liver cancer cases is expected to drive the growth of the primary biliary cholangitis market in the coming years. Liver cancer is a type of cancer that originates in liver cells. Primary biliary cholangitis is closely linked to liver cancer because the condition raises the risk of developing malignancies such as cholangiocarcinoma and hepatocellular carcinoma. The rising prevalence of liver cancer, along with complications associated with primary biliary cholangitis, is contributing to greater demand for effective diagnosis and treatment options. For instance, in January 2024, according to projections from the American Cancer Society, a leading professional organization in the United States, approximately 41,630 new cases of liver cancer were expected, including 28,000 cases in men and 13,630 in women. In addition, about 29,840 individuals, comprising 19,120 men and 10,720 women, were projected to die from the disease. Therefore, the growing incidence of liver cancer is supporting the expansion of the primary biliary cholangitis market.

Major companies operating in the primary biliary cholangitis market are concentrating on the development of innovative and specialized therapies, including orphan drug combinations such as obeticholic acid and bezafibrate, to strengthen treatment outcomes and secure market exclusivity. The combination of obeticholic acid and bezafibrate, supported by orphan drug designation, is intended to deliver a more comprehensive and effective approach to managing primary biliary cholangitis, with the potential to improve quality of life for patients affected by this rare condition. For instance, in May 2023, Intercept Pharmaceuticals, Inc., a US-based biopharmaceutical company, received orphan drug designation from the US Food and Drug Administration for the combination of obeticholic acid and bezafibrate, a peroxisome proliferator-activated receptor agonist, as a potential treatment for primary biliary cholangitis. Obeticholic acid, marketed as Ocaliva, is already approved for the treatment of primary biliary cholangitis in the United States.

In March 2023, Ipsen SA, a France-based pharmaceutical company, acquired Albireo Pharma, Inc. for an undisclosed amount. Through this acquisition, Ipsen aims to expand its rare disease portfolio by adding novel pipeline candidates, strengthening its focus on rare cholestatic liver diseases in both pediatric and adult populations, and enhancing its scientific and commercial capabilities. Albireo Pharma Inc. is a US-based biopharmaceutical company engaged in the development of A3907, a therapy targeting primary biliary cholangitis.

Major companies operating in the primary biliary cholangitis market are Pfizer Inc, F Hoffmann La Roche Ltd, Merck And Co Inc, Novartis AG, Bristol Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc, Dr Reddys Laboratories Ltd, Amneal Pharmaceuticals LLC, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, Intercept Pharmaceuticals Inc, Arrowhead Pharmaceuticals Inc, Calliditas Therapeutics AB, NGM Biopharmaceuticals Inc, Albireo Pharma Inc, Genfit SA, CymaBay Therapeutics Inc, Ascletis Pharma Inc, Ipsen Pharma, Ferring Pharmaceuticals.

North America was the largest region in the primary biliary cholangitis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the primary biliary cholangitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the primary biliary cholangitis market by increasing costs of imported diagnostic imaging systems, laboratory reagents, specialty pharmaceuticals, and advanced medical devices. Healthcare providers in North America and Europe are most affected due to reliance on imported diagnostic and treatment technologies, while Asia-Pacific faces higher costs for specialty drug manufacturing inputs. These tariffs are contributing to increased treatment and diagnostic expenses. However, they are also supporting local pharmaceutical production, regional diagnostic development, and innovation in cost-effective management solutions for rare liver diseases.

The primary biliary cholangitis market research report is one of a series of new reports that provides primary biliary cholangitis market statistics, including primary biliary cholangitis industry global market size, regional shares, competitors with a primary biliary cholangitis market share, detailed primary biliary cholangitis market segments, market trends and opportunities, and any further data you may need to thrive in the primary biliary cholangitis industry. This primary biliary cholangitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Primary biliary cholangitis (PBC) is a long-term autoimmune liver disorder marked by ongoing inflammation and gradual destruction of the small bile ducts within the liver. This disease can result in disrupted bile flow, liver injury, and a range of associated complications. PBC most commonly affects middle-aged women and is frequently linked with symptoms such as fatigue, itching, and abdominal discomfort.

The main treatment options for primary biliary cholangitis include drug therapy and liver transplantation. A drug is any chemical substance that produces a change in an organism’s physiological or psychological functions when administered, and ursodeoxycholic acid (UDCA) is considered the standard first-line therapy for PBC, as it helps improve liver function, decrease liver inflammation, and slow disease progression. Primary biliary cholangitis is diagnosed using imaging techniques such as magnetic resonance elastography, magnetic resonance cholangiopancreatography, ultrasound, fibroscan, along with blood tests, cholesterol tests, antibody tests, liver function tests, and others. These diagnostic and treatment services are utilized by end users including specialty clinics, homecare settings, and others.

The primary biliary cholangitis market includes revenues earned by entities by providing services such as psychosocial support services, nutritional guidance services, medical diagnosis, and specialized medical care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The primary biliary cholangitis market also includes sales of products such as fat-soluble vitamins, anti-itch medications, and imaging equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.